Company Analysis
Sign in

Enliven Therapeutics, Inc. (ELVN)

Nasdaq: ELVN · Pharmaceutical Preparations · Boulder, CO · filing with the SEC since 2016
Full chart Alerts Compare
Grade4.9
◀ Past 4.2● Present 5.6▶ Future 4.8
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income-$104M-16.5%
Earnings per share$-1.83+3.2%
Operating cash flow-$70.3M+3.9%
Cash$98.9M-20.4%
Debtn/a
Shareholders’ equity$460M+48.3%
Shares, diluted56.7M+20.4%
Return on equity-22.6%
The recordfrom its filings
Filings in 2026113
Newest filingNov 5 · 10-Q
Annual reportMar 3, 2026
Quarterly reportNov 5, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$76.9M
Insider buys, 12 months$0.00
Patents granted6
Filer categoryNon-accelerated filer
Trailing twelve months to Sep 2026Net income -$113MCash from operations -$66.2Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 5, 2026 · SEC EDGAR · Form 10-Q
Quarterly report
Open the filing on sec.gov
Nov 5, 2026 · SEC EDGAR · Form 8-K
Results released
Open the filing on sec.gov
Nov 3, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 21, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 21, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 16, 2026 · SEC EDGAR · Form 4
Insider trade report
Open the filing on sec.gov
Oct 14, 2026 · SEC EDGAR · Form 8-K
Current report
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton ELVN · research, not advice